Paper Details

  1. Home
  2. Paper Details

A double masked randomised 4-week, placebo-controlled study in the USA, Thailand and Taiwan to compare the efficacy of oral valganciclovir and topical 2% ganciclovir in the treatment of cytomegalovirus anterior uveitis: study protocol.

Author: AcharyaNisha R, DoanThuy A, GebreegziabherElisabeth A, GonzalesJohn A, JoyeAshlin S, KeenanJeremy D, LaovirojjanakulWipada, LietmanThomas M, LinChang-Ping, PorcoTravis C, Rose-NussbaumerJennifer, SeitzmanGerami D, SomkijrungrojThanapong, TakharJaskirat S

Clinical Trial ProtocolA plan for conducting a clinical trial. It describes in detail the purpose, design, methodology, and statistical considerations of the trial, ensuring the transparency and consistency of the trial.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study explores the potential benefits of topical ganciclovir solution for CMV anterior uveitis. Topical ganciclovir may be a safer, more cost-effective, and convenient treatment option compared to oral valganciclovir.
Paper Details　
Original Abstract of the Article :
Cytomegalovirus (CMV) anterior uveitis is a recognised cause of anterior uveitis in immunocompetent patients and is preventable cause of vision loss. Ocular sequelae include corneal endothelial damage which can cause corneal oedema and failure, as well as glaucoma. Recurrences of inflammation are co...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937053/

データ提供：米国国立医学図書館（NLM）

Comparing Treatment Strategies for Cytomegalovirus Anterior Uveitis

This study investigates the efficacy and safety of two different treatment options for cytomegalovirus (CMV) anterior uveitis, a common cause of anterior uveitis in immunocompetent patients. The researchers conducted a randomized controlled trial comparing oral valganciclovir with topical 2% ganciclovir in patients with CMV anterior uveitis. This research, like a journey across different landscapes, seeks to find the most effective treatment for a potentially sight-threatening condition.

A Desert Oasis of Treatment Options

The study aims to determine the relative effectiveness of oral valganciclovir, often associated with systemic side effects, and topical 2% ganciclovir, a potentially safer and more convenient option. This comparative approach, like navigating different desert paths, seeks to identify the most effective and safe treatment for patients with CMV anterior uveitis.

A Quest for Optimal Eye Care

This research, like a quest for a rare desert treasure, aims to find the most effective treatment for CMV anterior uveitis, a condition that can significantly impact vision. By comparing different treatment options, the study provides valuable insights into the management of this eye disease and helps optimize patient care.

Dr.Camel's Conclusion

This study, like a compass pointing the way across the desert, compares different treatment strategies for cytomegalovirus anterior uveitis, offering valuable insights for ophthalmologists and patients seeking optimal eye care.

Date :
  1. Date Completed 2020-12-31
  2. Date Revised 2020-12-31
Further Info :

Pubmed ID

31862739

DOI: Digital Object Identifier

PMC6937053

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.